EffRx Pharmaceuticals
Stage
Secondary Market | AliveTotal Raised
$10.25MAbout EffRx Pharmaceuticals
EffRx Pharmaceuticals exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential. Once developed, the company partners these products with established pharmaceutical companies. EffRx's goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying our technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action.
EffRx Pharmaceuticals Headquarter Location
Wolleraustrasse 41B
Freienbach, CH-8807,
Switzerland
+41 44 503 78 60
Expert Collections containing EffRx Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
EffRx Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
EffRx Pharmaceuticals Patents
EffRx Pharmaceuticals has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/5/2011 | 3/14/2017 | Excipients, Conditions of the mucous membranes, Oral mucosal pathology, Salivary gland pathology, Dosage forms | Grant |
Application Date | 12/5/2011 |
|---|---|
Grant Date | 3/14/2017 |
Title | |
Related Topics | Excipients, Conditions of the mucous membranes, Oral mucosal pathology, Salivary gland pathology, Dosage forms |
Status | Grant |
Latest EffRx Pharmaceuticals News
May 13, 2022
13 May 2022 | News Image credit: shutterstock EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and Vector Pharma, announced the newly formed World Orphan Drug Alliance (WODA). WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patient programs through to full commercialization. By bringing together experts for rare diseases, WODA has capabilities to provide all the services necessary for orphan medicines to reach patients in need, replacing local branches of global distributors or multinational companies. In total, WODA covers 68 countries in the following regions: Turkey, Middle East and North Africa, Russia and CIS region, Central and Eastern Europe, Latin America and Switzerland. About Founding Partners: EffRx Pharmaceuticals is a Switzerland based company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. Medis based in Slovenia is the commercialization partner of choice for innovative pharmaceutical and biotech companies seeking strong business growth in Central and Eastern Europe. Orpharm is a Moscow based full-service distributor covering Russia and the Commonwealth of Independent States (CIS). OrphanDC based in Sao Paolo, Brazil acts as a partner for biotech companies in Latin America. They focus on supporting their clients from the clinical development stage throughout the product lifecycle. Vector Pharma is a Dubai based full-service distributor covering Middle East, North Africa and Turkey. Sign up for the editor pick and get articles like this delivered right to your inbox. Name *
EffRx Pharmaceuticals Web Traffic
EffRx Pharmaceuticals Rank
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.